Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma (TRIPLE-PATH)

6 maggio 2026 aggiornato da: Le Qu, Jinling Hospital, China

A Prospective, Open-label, Phase II Clinical Trial of Perioperative Toripalimab Plus Lenvatinib for Multi-stage Clear Cell Renal Cell Carcinoma (ccRCC)

The IO/TKI regimens which combines Immune checkpoint inhibitors (IO) with Tyrosine Kinase Inhibitors (TKI) have become the standard first-line option for advanced ccRCC. Currently, IO/TKI regimens are serving as neoadjuvant treatment in arising clinical trials for ccRCC. Although anatomical change reflected by radiological response is reported in most neoadjuvant trials, only few studies focus on evaluation for pathological response in ccRCC.

The TRIPLE-PATH trial is an investigator initiated prospective, open-label phase II trial with the main objective to evaluate the clinical activity of preoperative/neoadjuvant therapy of toripalimab plus lenvatinib as mesured by pathological response of resected primary lesion in multi-stage ccRCC. Patients with ccRCC will be enrolled into 3 different cohorts based on their clinical TNM at the time of screening: localized ccRCC (cT1-2N0M0), locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0), and metastatic ccRCC (cTanyNanyM1). Toripalimab (240mg Q3W) will be administered intravenously on the 1st day, and lenvatinib (20mg QD) will be administered orally once daily of each 3 weeks cycle. Patients in all cohorts will receive 4 cycles of preopertive/neoadjuvant toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO), and a subsequent partial/radical nephrectomy 7-10 days after the last cycle. For adjuvant/postoperative treatment, patients who undergo R0 resection presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany will receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED) will also receive adjuvant doses of toripalimab (240mg Q3W IV) for 17 cycles; patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive postoperative doses of toripalimab (240mg Q3W IV) plus lenvatinib (20mg QD PO) for 17 cycles.

Specific follow-up for the enrolled patients is required in the TRIPLE-PATH trial. Longitudinal CT/MRI is utilized to assess the radiological response. Tissues and body fluid samples collected from the patients will be utilized for biomarker and multi-omic analysis.

The primary endpoint of the TRIPLE-PATH trial is major pathological response (MPR) in the primary lesion according to the pathological response reporting guidelines by the International Neoadjuvant Kidney Cancer Consortium (INKCC). Simon's two-stage minimax design is adopted by TRIPLE-PATH. An initial of 12 patients per cohort (36 in total) will be recruited, following an interim analysis. Recruitment to any cohort will be suspended if MPR is not observed in any patient at the interim analysis. If MPR is observed in at least 1 patient, additional 9 patients will be recruited in each cohort to at most 21 patients. Considering potential 15% dropout rate in each cohort, an anticipation of 25 patients will be recruited for each cohort (75 in total) in this study.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Tipo di studio

Interventistico

Iscrizione (Stimato)

75

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Jiangsu
      • Nanjing, Jiangsu, Cina, 210000
        • Reclutamento
        • Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Contatto:
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Patients have fully understood and give written informed consent prior to receive neoadjuvant therapy. Patients with history of major psychiatric disease must be judged able to fully understand the trial, and the explicit consent of family members is required;
  • Patients with the ages range from 18 to 80 years old (at the time of signing informed consent);
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1;
  • Patients have at least 1 measurable target lesion according to RECIST v1.1. The target lesion can be biopsied as per protocol.
  • Histologically confirmed clear cell RCC;
  • Patients will be enrolled into 3 separate cohorts based on their clinical TNM at the time of baseline screening:

    1. Cohort 1: localized ccRCC (cT1-2N0M0): the primary tumor in this cohort must meet the subsequent criteria:

      • The cT1a primary tumor should have ≥10 R.E.N.A.L. score, or locate in renal hilum close to renal artery or its main branch;

        • Patients with cT1b-2b primary tumors can be directly enrolled;

          • In case of necessary, patients will undergo dual radiological examinations using contrast-enhanced CT and MRI to rule out potential invasion of the renal pelvis or perirenal fat as per protocol.
    2. Cohort 2: locally advanced ccRCC (cT3-4N0M0 or cTanyN1M0);
    3. Cohort 3: metastatic ccRCC (cTanyNanyM1): the patients should be evaluated as suitable for cytoreductive nephrectomy.

      • Patient have no symptomatic metastatic lesions requiring urgent intervention;

        • The sum of the diameters of the other target lesions (excluding the primary tumor) does not exceed the longest diameter of the primary tumor.
  • The patients who are treatment-naive, and have not received systemic therapy for any tumor;
  • Adequate main organ function. The screening laboratory indicators must meet the following criteria:

    1. Hemoglobin ≥ 90 g/L (Without blood transfusion);
    2. Platelets count ≥ 100 x 109/L;
    3. Absolute neutrophil count ≥ 1.5 x 109/L;
    4. Serum creatinine ≤ 1.5 x ULN, or eGFR > 60 mL/min/1.73m2;
    5. Total bilirubin ≤ 1.5 mg/dL;
    6. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 2.5 x ULN for patients without evidence of liver metastases; AST and/or ALT ≤ 5 x ULN for patients with liver metastases;
    7. Normal CK;
    8. Normal Troponin T;
    9. Normal LDH.
  • Willingness and ability to comply with planned visits, therapeutic laboratory testing, and other procedures.

Exclusion Criteria:

  • Signs of tumor metastasis involving the central nervous system, or radiological evidence of brain metastasis;
  • History of malignant tumors other than ccRCC within the previous 5 years, with the exception of malignant tumors that can be expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with radical surgery);
  • Prior to participating in the study, patients have received prior immune checkpoint inhibitors, investigational drugs or device therapy;
  • History of undergoing major surgery (judged by the investigator) within 4 weeks before the first trial dose, are recovering, or are unable to undergo baseline puncture;
  • History of severe drug allergy, including but not limited to antibody drugs;
  • Patients with contraindications to immunotherapy restart, including but not limited to:

    1. Grade 2-4 immune myocarditis;
    2. Severe grade 4 proteinuria;
    3. Severe or life-threatening grade 4 immune hepatitis;
    4. Severe grade 3-4 immune pneumonitis;
    5. Severe inflammatory arthritis that significantly affects daily life or quality of life;
    6. Severe neurological toxicity:
    7. Myasthenia gravis grade 2-4;
    8. Guillain-Barre syndrome (GBS) or transverse myelitis of any grade;
    9. Grade 2-4 encephalitis;
    10. Severe or life-threatening grade 3-4 pancreatitis;
    11. Severe or life-threatening bullous disease (grade 3-4);
    12. Severe grade 3-4 uveitis or episcleritis.
  • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or long-term corticosteroid therapy.
  • Non-resolution of toxicity after previous antineoplastic therapy, i.e., resolution to baseline, CTCAE v5.0 grade 0-1 (excluding alopecia), or inclusion/exclusion criteria. Irreversible toxicities (e.g., hearing loss) that would not reasonably be expected to be exacerbated by the study drug can be included in the study;
  • Known history of clinically significant liver disease, including active viral hepatitis (hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HbcAb) positive, HBV DNA>10000 copies /mL or >2000 IU/mL; Hepatitis C virus (HCV) antibody positive and HCV RNA positive), or other active hepatitis, clinically significant moderate to severe cirrhosis;
  • Patients with uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc. (Patients who do not need drainage of effusion or stop drainage for 3 days without significant increase in effusion can be enrolled);
  • Receiving a systemic corticosteroid (prednisone > 10mg/ day or equivalent) or other immunosuppressive medication within 14 days before the first study medication;
  • Patients with any severe and/or uncontrolled disease, including:

    1. Hypertension that is not well controlled by antihypertensive medication;
    2. Unstable angina pectoris or myocardial infarction, coronary artery bypass grafting or stent implantation within 6 months before study medication;
    3. Grade I or above myocardial ischemia or myocardial infarction, arrhythmia (including QTc≥480ms) and ≥ grade 2 congestive heart failure (New York Heart Association (NYHA) classification); Degree II or above heart block; Left ventricular ejection fraction (LVEF) < 50%;
    4. Poorly controlled diabetes (fasting blood glucose > 10 mmol/L);
    5. Patients with urinary protein ≥++ and confirmed 24-hour urinary protein > 1.0g;
    6. Severe active or uncontrolled infection.
  • Patients with or suspected to have active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.;
  • Renal failure requiring hemodialysis or peritoneal dialysis;
  • Patients with a history of immunodeficiency, including HIV positive patients, other acquired immunodeficiency diseases, congenital immunodeficiency diseases, or organ transplantation history;
  • History of live attenuated vaccine inoculation within 4 weeks before the first study drug or the expected vaccination during the study period;
  • History of psychiatric drug abuse and can not quit or have a history of mental disorders;
  • Women who are of childbearing potential. Women of childbearing potential must have a negative serum or urine pregnancy test, and must use appropriate methods of contraception.
  • The presence of any other severe, acute or chronic medical disease or mental illness or laboratory abnormality, as judged by the investigator, that may increase the risk associated with participation in the study or that may interfere with the interpretation of the results of the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental: Perioperative toripalimab + lenvatinib followed by a partial/radical nephrectomy

Toripalimab (240mg Q3W) will be administered intravenously on the 1st day of each 3 weeks cycle, and lenvatinib (20mg QD) will be administered orally once daily of each 3 weeks cycle. The patients will receive preoperative/neoadjuvant 4 cycles of toripalimab (240mg Q3W IV) plus lenvatinb (20mg QD PO) followed by a partial/radical nephrectomy 7-10 days after the last cycle.

Adjuvant 17 cycles of toripalimab (240mg Q3W IV) will start at 4-8 weeks after surgery, for patients who undergo R0 resection but presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany, or undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED).

Postoperative 17 cycles of toripalimab (240mg Q3W IV) plus lenvatinb (20mg QD PO) will start at 4-8 weeks after surgery, for patients who undergo R1 resection or presented with M1 disease cannot be definitely resected.

Patients will receive 4 cycles of preoperative/neoadjuvant toripalimab (240mg Q3W IV) followed by a partial/radical nephrectomy 7-10 days after the last cycle.

Patients who undergo R0 resection but presented with cT1-2aN0M0G4/cT2bN0M0G3-4/cT3-4N0M0Gany/cTanyN1M0Gany, or undergo simultaneous resection of all oligometastases considered as "no evidence of disease" (M1 NED), will receive 17 cycles of adjuvant toripalimab (240mg Q3W IV), starting at 4-8 weeks after surgery.

Patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive 17 cycles of postoperative toripalimab (240mg Q3W IV), starting at 4-8 weeks after surgery.

Adjustment of dose: For patients with grade 3 or greater adverse events according to CTCAE v5.0 suspected to be caused by toripalimab, the dose can be postponed. In case of SAE, the dose can be discontinued. Dose de-escalation can be decided in patients who achieve MPR in primary lesions by investigators as per protocol.

Altri nomi:
  • anticorpo monoclonale anti-PD-1

Patients will receive 4 cycles of preoperative/neoadjuvant lenvatinib (20mg QD PO) of each 3 weeks cycle followed by a partial/radical nephrectomy 7-10 days after the last cycle.

Patients who undergo R1 resection or presented with M1 disease cannot be definitely resected will receive 17 cycles of postoperative lenvatinib (20mg) orally once daily of each 3 weeks cycle, starting at 4-8 weeks after surgery.

Adjustment of dose: For patients with grade 3 or greater adverse events according to CTCAE v5.0 suspected to be caused by lenvatinib, the dosage can be gradually reduced to 16mg, 12mg and a minimal of 8mg. In case of SAE, the dose can be discontinued. Dose de-escalation can be decided in patients who achieve MPR in primary lesions by investigators as per protocol.

Altri nomi:
  • Lenvatinib mesilato (USAN)
  • Multi-Kinase Inhibitor

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Major Pathological Response Rate
Lasso di tempo: Within 1 week after nephrectomy
MPR is defined as the total proportion of viable residual tumor cells in the tumor bed via H-E stained sections of the resected tumor according to the guidelines by INKCC. Major pathological response rate is defined as the proportion of patients achieving MPR in their primary lesion.
Within 1 week after nephrectomy

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety according to Adverse Events
Lasso di tempo: From baseline to 12 weeks after last dose
The frequency and percentage of patients experiencing adverse events (AEs) according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).
From baseline to 12 weeks after last dose
Surgical morbidity
Lasso di tempo: Up to 4 weeks after nephrectomy
Surgical morbidity or complications rate after neoadjuvant therapy. Intraoperative adverse incidents are defined as adverse events due to surgical intervention occurring between skin incision and closure and are evaluated according to the EAU intraoperative AI classification (EAUiaiC). Postoperative complications are evaluated according to Clavien-Dindo classification system.
Up to 4 weeks after nephrectomy
Best Overall Response
Lasso di tempo: From baseline to 12 weeks
BOR is defined as the best response state among all the longitudinal evaluation according to RECIST v1.1. A modified BOR only focusing on metastases will be specially utilized for patients in cohort 3.
From baseline to 12 weeks
Down-staging Rate of Primary T Stage
Lasso di tempo: From baseline to 12 weeks
The T stage of the primary lesion will be evaluated according to the 8th edition of AJCC at baseline and surgery to reflect the change in T stage of the primary lesion after neoadjuvant therapy.
From baseline to 12 weeks
Change in R.E.N.A.L. Score of Primary Lesion
Lasso di tempo: From baseline to 12 weeks
The R.E.N.A.L. score can reflect the difficulty of the nephrectomy. The R.E.N.A.L. scores of the patients before and after neoadjuvant therapy will be evaluated based on the CT/MRI scan.
From baseline to 12 weeks
Rate of R0 Resection
Lasso di tempo: Within 1 week after nephrectomy
R0 resection is defined as no visible tumor cells were observed at the surgical margins of the pathological specimens.
Within 1 week after nephrectomy
Change in Tumor Thrombus
Lasso di tempo: From baseline to 12 weeks
For patients with TT at baseline, the change of TT according to Mayo's classification will be recorded.
From baseline to 12 weeks
Change in Renal Function
Lasso di tempo: Up to 1 year after nephrectomy
The change in renal function before and after neoadjuvant therapy,also before and after nephrectomy will be evaluated by eGFR. The eGFR will be calculated using the CKD-EPI formula. Split renal function recovery rate will be report in patients who undergo partial nephrectomy.
Up to 1 year after nephrectomy
Progression Free Survival
Lasso di tempo: Up to 5 years after treatment
PFS is defined as the time from enrollment to progression disease, recurrence, distant metastasis or death from any cause.
Up to 5 years after treatment
Disease Free Survival
Lasso di tempo: Up to 5 years after nephrectomy
DFS is defined as the time from completion of nephrectomy to recurrence, distant metastasis or death from any cause. DFS will only be reported in the cohort 1 and 2.
Up to 5 years after nephrectomy
Overall Survival
Lasso di tempo: Up to 5 years after treatment
OS is defined as the time from enrollment to death from any cause.
Up to 5 years after treatment

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Tissue-based Biomarker Analysis
Lasso di tempo: Up to 2 years after treatment
Biopsied and resected tumor specimens will be collected for revealing changes in the tumor microenvironment.
Up to 2 years after treatment
Peripheral Plasma-based Biomarker Analysis
Lasso di tempo: Up to 2 years after treatment
Baseline, during-treatment, pre-operative, and postoperative peripheral plasma will be collected for revealing potential cycling biomarkers.
Up to 2 years after treatment
Radiological and Pathological Biomarker Analysis
Lasso di tempo: Up to 2 years after treatment
The radiological and pathological information during the treatment process will be collected. A prediction model related to therapeutic efficacy and prognosis is anticipated to be developed.
Up to 2 years after treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Le Qu, M.D., Jinling Hospital, China

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 maggio 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2032

Date di iscrizione allo studio

Primo inviato

22 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 aprile 2026

Primo Inserito (Effettivo)

6 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

11 maggio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 maggio 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi